By finding existing low cost generic drugs with the potential to treat a rare disease, and in vivo gene therapy trials to test their effect on mice, GeNFindacure aimsto secure founding from investors to repurpose drugs and the unique use of in vivo gene therapy to treat rare diseases.

GeN is currently planning for a Series A funding round to develop and launch its Anti-Aging portfolio.

We welcome the opportunity to discuss our needs with interested investors.


At GeN we place an immense value on our customers.

GeN Ltd
Office 7 35-37 Ludgate Hill
London, England


diseño alauna